|
|
Volumn 25, Issue 13, 2007, Pages 1637-1638
|
|
Integrin inhibitors reaching the clinic
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CILENGITIDE;
FIBRIN;
FIBRINOGEN;
FIBROBLAST GROWTH FACTOR 2;
FIBRONECTIN;
GELATINASE A;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
INTEGRIN;
INTEGRIN INHIBITOR;
INTEGRIN LINKED KINASE;
LAMININ;
MITOGEN ACTIVATED PROTEIN KINASE;
MONOCLONAL ANTIBODY LM 609;
PROTEIN INHIBITOR;
PROTEIN KINASE B;
RAC PROTEIN;
S 247;
TEMOZOLOMIDE;
THROMBOSPONDIN;
UNCLASSIFIED DRUG;
VITRONECTIN;
VOLOCIXIMAB;
ADD ON THERAPY;
ANGIOGENESIS;
ANOREXIA;
APOPTOSIS;
ARTHRALGIA;
BLEEDING;
BONE PAIN;
BRAIN BLOOD FLOW;
CANCER RADIOTHERAPY;
CELL ADHESION;
CELL MIGRATION;
CELL PROLIFERATION;
CELL SURVIVAL;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONTINUOUS INFUSION;
DOSE RESPONSE;
DRUG DOSE INCREASE;
DRUG HALF LIFE;
EDITORIAL;
ELECTROLYTE DISTURBANCE;
GLIOBLASTOMA;
GLIOMA;
HUMAN;
NONHUMAN;
PRIORITY JOURNAL;
RECURRENT CANCER;
THROMBOCYTOPENIA;
THROMBOSIS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DOSE-RESPONSE RELATIONSHIP, DRUG;
GROWTH SUBSTANCES;
HUMANS;
INTEGRINS;
NEOPLASMS;
SNAKE VENOMS;
TREATMENT OUTCOME;
|
|
EID: 34249113455
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2006.09.8376 Document Type: Editorial |
|
Times cited : (113)
|
|
References (11)
|
